ENTOD Pharmaceuticals Announces Prof Vivek Padgaonkar as New Independent Director

ENTOD Pharmaceuticals has named Prof. Vivek Padgaonkar, who previously served as Director of the OPPI (Project & Policy), as a non-executive independent director. Prof. Padgaonkar's background includes significant contributions to various lobbying and think-tank organizations focused on healthcare, and his work with multiple government ministries has played a crucial role in shaping contemporary pharmaceutical policies. Additionally, he serves as an independent director at Martin & Harris Labs, Bervin Investment & Leasing, and Juvenor Healthcare.

Established in 1977, ENTOD Pharmaceuticals is an Indian company renowned for its research-driven approach in ophthalmology, ENT, and dermatological medicine. With over 30 years of expertise, ENTOD operates in more than 67 countries and is at the forefront of developing innovative molecules using generative AI platforms in the fields of ophthalmic, ENT, and skincare treatments.

Dr Vivek Padgaonkar explained his excitement about joining the board by saying, “I am honoured to join ENTOD Pharmaceuticals and contribute to its mission of driving innovation in the pharmaceutical industry. This is a remarkable opportunity to leverage my experience with a company at the forefront of technological advancements.”

Nikkhil K Masurkar, CEO of ENTOD Pharmaceuticals, said, “We are thrilled to welcome Prof Padgaonkar to our board. His insights will be crucial in our ongoing efforts to develop novel solutions using advanced AI technologies, pushing our vision of a future-ready pharmaceutical industry.”

Earlier this year, ENTOD Pharmaceuticals launched its state-of-the-art research and development center. This DSIR-approved facility boasts cutting-edge tools for molecular and formulation research, advanced microbiology testing capabilities, sterile batch production infrastructure, and sophisticated quality assurance and quality control analytical equipment.